Cephalon Inc. (CEPH)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

41 MOORES ROAD FRAZER, PA 19355

Cephalon is a biopharmaceutical company engaged in the discovery, development and commercialization of medications, with a particular focus on central nervous system disorders, pain, oncology, inflammatory disease and regenerative medicine. Co. markets and sells directly or through partnerships 150 different branded and generic products in nearly 100 countries worldwide. Co.'s products include among others, NUVIGIL and PROVIGIL, for the treatment of excessive sleepiness associated with narcolepsy; GABITRIL, for the treatment of partial seizures in epileptic patients, and FENTORA for the management of pain in patients with cancer who are already receiving and tolerant to opioid therapy.

View SEC Filings from CEPH instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 1 1 0.0% (0.0%) (0.0%)
13F shares: 1 1 0.0%
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CEPH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CEPH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

EGAN WILLIAM P

  • Director
No longer subject to file 2011-10-14 0

PAPPERT GERALD J. EXEC VP & GENERAL COUNSEL

  • Officer
0 2011-10-14 0

GREENACRE MARTYN D

  • Director
No longer subject to file 2011-10-14 0

KAILIAN VAUGHN M

  • Director
No longer subject to file 2011-10-14 0

MOLEY KEVIN E

  • Director
No longer subject to file 2011-10-14 0

WILENSKY GAIL R

  • Director
No longer subject to file 2011-10-14 0

WINGER DENNIS L

  • Director
No longer subject to file 2011-10-14 0

VAUGHT JEFFRY L EXEC VP, CHIEF SCIENTIFIC OFF

  • Officer
No longer subject to file 2011-10-14 0

RUSSELL LESLEY EXEC VP, CHIEF MEDICAL OFF

  • Officer
No longer subject to file 2011-10-14 0

SAVINI CARL A EXEC VP, CHIEF ADMIN OFF

  • Officer
No longer subject to file 2011-10-14 0

BUCHI J KEVIN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
No longer subject to file 2011-10-14 0

BALDASSANO VALLI F. EXEC VP, CHIEF COMPLIANCE OFF

  • Officer
No longer subject to file 2011-10-14 0

GROENHUYSEN WILCO EXEC VP & CFO

  • Officer
0 2011-10-14 0

ARAGUES ALAIN EXEC VP, PRESIDENT EUROPE

  • Officer
No longer subject to file 2011-10-14 0

HOMCY CHARLES J

  • Director
No longer subject to file 2011-10-14 0

GREBOW PETER E EXEC. V.P., CEPHALON VENTURES

  • Officer
70,974 2010-12-20 0

BALDINO FRANK JR CHAIRMAN AND CEO

  • Officer
  • Director
520,083 2010-12-13 0

SANDERS CHARLES A

  • Director
0 2010-05-20 0

ROCHE ROBERT P JR EXEC. VP, WW PHARM OPS

  • Officer
50,582 2009-12-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments